JSR Corporation
JSCPY
Other OTC25.26
USD
+0.26
- -
CIK
0001449005
ISIN
US46632X1063
CUSIP
46632X106
Return %
Stock
S&P500
1Y
-3.95
16.28
3Y
-33.92
62.37
5Y
36.17
67.63
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Eric R. Johnson
- Full Time Employees
- 7,997
- Sector
- Basic Materials
- Industry
- Chemicals - Specialty
- Address
- Shiodome Sumitomo Building Tokyo Japan 105-8640
- IPO Date
- May 14, 2010
- CIK
- 0001449005
- Website
- jsr.co.jp
- Similar Companies
- Business
- JSR Corporation develops and manufactures advanced materials for semiconductors, displays, life sciences, and plastics. The company produces semiconductor materials including lithography materials such as photoresists and underlayers, chemical mechanical planarization slurries and cleaning solutions, and advanced packaging materials; display materials encompassing LCD panel materials and functional coatings as well as next-generation OLED materials; optical solutions featuring heat-resistant transparent resins and films, high-performance UV curable resins, and stereolithography systems; life sciences products and services comprising bioprocess materials like Protein A affinity chromatography resins including Amsphere A3 and A+, contract development and manufacturing organization services, contract research organization services, diagnostic reagents, and drug discovery support; and plastics such as ABS, AES, AS, and ASA resins for automotive parts, appliances, and building materials; alongside other offerings like Holter ECG monitoring services and emulsions. Founded in 1957 as Japan Synthetic Rubber Co., Ltd. and headquartered in Tokyo, Japan, JSR operates globally across Asia, Europe, and North America, serving electronics, automotive, pharmaceutical, and biotechnology sectors. In recent developments, JSR completed the acquisition of Yamanaka Hutech Corporation in August 2024 to expand its high-purity chemicals and semiconductor film-forming technologies; entered a cross-licensing and collaboration agreement with Lam Research and Inpria in September 2025 for advanced EUV resists and etching solutions; announced in October 2025 the sale of its chromatography business including Amsphere resins to MilliporeSigma; transferred its in vitro diagnostic business including Medical & Biological Laboratories and JSR Life Sciences to Tokuyama Corporation in 2025; merged with parent JICC-02 Ltd. in 2024 leading to delisting from the Tokyo Stock Exchange; and launched Amsphere A+ Protein A resin in September 2024 while forming alliances such as with Metagen Therapeutics for microbiome drug manufacturing.
Exclusive: Japan state-backed fund considering sale of chipmaking materials maker JSR, sources say
Lam Research Teams Up With JSR: Can it Lead in High-NA EUV?
Lam Research and JSR Corporation/Inpria Corporation Enter Cross-Licensing, Collaboration Agreement to Advance Semiconductor Manufacturing
Essential Japanese Semi Companies For The Reshoring Age
4 Top Stocks to Ride the Upturn in Chemical Plastics Industry